Christensen Hanne, Casolla Barbara, Frontera Jennifer A, Grundtvig Josefine, Nielsen Jørn Dalsgaard, Petersson Jesper, Steiner Thorsten
Department of Neurology, Bispebjerg-Frederiksberg University Hospital, Kobenhavn, Denmark.
Stroke Unit, CHU Pasteur 2, Université Cote d'Azur, UMR2CA URRIS), Nice, France.
Eur Stroke J. 2025 Apr;10(1_suppl):4-13. doi: 10.1177/23969873231222393. Epub 2025 May 22.
The incidence of intracerebral hemorrhage (ICH) associated with oral anticoagulants (OAC) is about one in five cases of ICH and associated with severe clinical presentation, frequently rapid clinical deterioration, and 30-days mortality of app 50%. This narrative review gives an overview of presentation and acute treatment of OAC-ICH. Oral anticoagulants do not cause ICH but lead to prolongation of bleeding and higher risk of hematoma expansion (HE). Clinicoradiological characteristics of oral anticoagulant associated ICH are not different from ICH in general. The therapeutic principle of reversal is to prevent or limit HE. The mode of action of the reversal agents for vitamin K antagonists, direct oral thrombin inhibitor and direct oral factor Xa inhibitors are described in the main text. We also discuss the principles of blood pressure lowering in the setting of acute OAC-ICH as it may be the second driving force of HE. Stroke unit care is needed to prevent further complications. Data from randomized controlled trials and observational data from unselected patients are needed to make stronger and more precise recommendations on acute therapy.
与口服抗凝剂(OAC)相关的脑出血(ICH)发生率约占脑出血病例的五分之一,且与严重的临床表现、频繁的快速临床恶化以及约50%的30天死亡率相关。本叙述性综述概述了OAC-ICH的临床表现和急性治疗。口服抗凝剂不会导致脑出血,但会导致出血时间延长和血肿扩大(HE)的风险增加。口服抗凝剂相关脑出血的临床放射学特征与一般脑出血并无不同。逆转治疗的原则是预防或限制血肿扩大。正文描述了维生素K拮抗剂、直接口服凝血酶抑制剂和直接口服Xa因子抑制剂的逆转剂作用方式。我们还讨论了急性OAC-ICH时血压降低的原则,因为它可能是血肿扩大的第二个驱动因素。需要卒中单元护理以预防进一步并发症。需要来自随机对照试验的数据和未选择患者的观察性数据,以便就急性治疗提出更强有力和更精确的建议。